Default company panoramic image
Logo

ImmuneWorks, Inc

We are developing a phase II ready asset for idiopathic pulmonary fibrosis, a deadly lung disease with an addressable market of $2.8bn.

  • Stage Product In Development
  • Industry Biotechnology
  • Location United States
  • Currency USD
  • Founded January 2006
  • Employees 5
  • Website immuneworks.com

Company Summary

We are developing an asset for the treatment of idiopathic pulmonary fibrosis (IPF) a deadly lung disease with 3-year mean survival after diagnosis and for which there are no approved drugs for the 125,000 U.S. IPF patients. ImmuneWorks asset was safe and signals of its ability to halt lung function decline were seen in a phase 1 clinical trial. We are raising capital to conduct a Phase 2 clinical trial that will lead to an exit via trade sale.

Team

  • Default avatar
    Wade Lange
    President & CEO

  • Default avatar
    David Wilkes, MD
    Founder and Chief Science Officer

  • Default avatar
    Michael Klemsz, PhD
    Founder and Vice President of Research

  • Default avatar
    Terrence Chew, MD
    Head of Clnical Development and Regulatory Affairs

  • Default avatar
    Katia Rothhaar, PhD
    Director, Research Operations

Advisors

  • Default avatar
    General Business: Ice Miller; Intellectual Property: Cooley, LLP
    Lawyer
    Unconfirmed
    Default avatar
    Milestone Advisors
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Indiana Seed Fund I
    Unconfirmed
    Default avatar
    Indiana Economic Development Corporation
    Unconfirmed
    Default avatar
    Bohemian Asset Management
    Unconfirmed